These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 29338538)

  • 1. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
    Lyons T; Carhart-Harris RL
    J Psychopharmacol; 2018 Jul; 32(7):811-819. PubMed ID: 29338538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of psilocybin therapy on personality structure.
    Erritzoe D; Roseman L; Nour MM; MacLean K; Kaelen M; Nutt DJ; Carhart-Harris RL
    Acta Psychiatr Scand; 2018 Nov; 138(5):368-378. PubMed ID: 29923178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics, Personality and Political Perspectives.
    Nour MM; Evans L; Carhart-Harris RL
    J Psychoactive Drugs; 2017; 49(3):182-191. PubMed ID: 28443703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
    Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
    JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.
    Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL
    Psychopharmacology (Berl); 2018 Feb; 235(2):459-466. PubMed ID: 29085980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
    McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
    J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
    Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; Mansur RB; McIntyre RS
    J Affect Disord; 2024 Jun; 355():342-354. PubMed ID: 38570038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
    Erritzoe D; Barba T; Spriggs MJ; Rosas FE; Nutt DJ; Carhart-Harris R
    J Psychopharmacol; 2024 May; 38(5):458-470. PubMed ID: 38520045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
    Garcia-Romeu A; Griffiths RR; Johnson MW
    Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.
    Madsen MK; Fisher PM; Stenbæk DS; Kristiansen S; Burmester D; Lehel S; Páleníček T; Kuchař M; Svarer C; Ozenne B; Knudsen GM
    Eur Neuropsychopharmacol; 2020 Apr; 33():71-80. PubMed ID: 32146028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
    Noorani T; Garcia-Romeu A; Swift TC; Griffiths RR; Johnson MW
    J Psychopharmacol; 2018 Jul; 32(7):756-769. PubMed ID: 29938565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
    Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
    Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.